196 374

Cited 0 times in

MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide-Based Chemoradiotherapy: A Single-Institution Study

DC Field Value Language
dc.contributor.author김영석-
dc.date.accessioned2015-12-24T08:46:21Z-
dc.date.available2015-12-24T08:46:21Z-
dc.date.issued2012-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/134188-
dc.descriptionDept. of Medicine/석사-
dc.description.abstractPurpose: Recently, cells deficient in O6-methylguanine–DNAmethyltransferase (MGMT) were found to show increased sensitivity totemozolomide (TMZ). We evaluated whether hypermethylation of MGMT wasassociated with survival in patients with glioblastoma multiforme (GBM).Methods and Materials: We retrospectively analyzed 93 patients withhistologically confirmed GBM and who received involved field radiotherapywith TMZ from 2001 to 2008. The median age was 58 years (range, 24-78).Surgical resection was total in 39 patients (42%), subtotal in 30 patients (32%),partial in 17 patients (18%), and only a biopsy was performed in seven patients(8%). Post-operative radiotherapy began within 3 weeks of surgery in 87% ofthe patients. Radiotherapy doses ranged from 50-74 Gy (median 70 Gy).MGMT gene methylation was determined in 78 patients; MGMT wasunmethylated in 43 patients (55%) and methylated in 35 patients (45%). Themedian follow-up period was 22 months (range, 3-88) for all patients.Results: The median overall survival (OS) was 22 months, and progression-freesurvival (PFS) was 11 months. MGMT gene methylation was an independentlysignificant prognostic factor for both OS (p=0.002) and PFS (p=0.008) inmultivariate analysis. The median OS was 29 months for the methylated group,and 20 months for the unmethylated group. In 35 patients with methylatedMGMT genes, the 2-year and 5-year OS rates were 54% and 31%, respectively.Six patients with combined prognostic factors of methylated MGMT genes,≤50 years, and total/subtotal resections are all alive 38-77 months afteroperation, whereas the median OS in eight patients with unmethylated MGMTgenes, >50 years, and less than subtotal resection was 13.2 months.Conclusion: We confirmed that MGMT gene methylation is a potentprognostic factor in patients with GBM. Our results suggest that earlypost-operative radiotherapy and a high total/subtotal resection rate might furtherimprove the outcome.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.publisherGraduate School, Yonsei University-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleMGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide-Based Chemoradiotherapy: A Single-Institution Study-
dc.title.alternativeTemozolomide-Based Chemoradiotherapy를 받은 아교모세포종 환자에서, 중요한 예후 인자로써의 MGMT gene promoter methylation-
dc.typeThesis-
dc.contributor.alternativeNameKim, Young Suk-
dc.type.localThesis-
Appears in Collections:
1. College of Medicine (의과대학) > Others (기타) > 2. Thesis

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.